Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer - PubMed (original) (raw)

Clinical Trial

Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer

L M Kuroki et al. Ann Surg Oncol. 2015 Mar.

Abstract

Background: Sarcopenia or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. This study aimed to examine the impact of sarcopenia on surgical complications and survival outcomes in patients with endometrial cancer.

Methods: A retrospective review of endometrial cancer patients who underwent surgery between 2005 and 2009 was performed. Sarcopenia was assessed on preoperative computed tomography (CT) scan by measurement of the lumbar psoas muscle cross-sectional area and defined as any value below the median (<4.33 cm(2)). Sarcopenic obesity was defined as sarcopenia plus a body mass index (BMI) of 30 kg/m(2) or higher. Microsatellite instability (MSI) was analyzed using the National Cancer Institute (NCI) consensus markers and tumor from hysterectomy specimens.

Results: Of 122 patients, 27 (22%) met the criteria for sarcopenic obesity. Sarcopenic patients were older than patients with normal muscle mass (mean age, 69.7 vs. 62.1 years; p < 0.001), had a lower BMI (31.1 vs. 39.4 kg/m(2); p < 0.001), and had more comorbidities (p = 0.048). Sarcopenia was not associated with tumor MSI, hospital stay, 90-day readmission rate, or early/late complications. Patients with sarcopenia had a shorter recurrence-free survival than nonsarcopenic patients (median 23.5 vs. 32.1 months; log-rank p = 0.02), but did not differ in terms of overall survival (log-rank p = 0.25). After adjustment for race, BMI, lymphocyte count, and tumor histology, sarcopenia was associated with a fourfold shorter recurrence-free survival (adjusted hazard ratio [HRadj], 3.99; 95% confidence interval [CI], 1.42-11.3).

Conclusions: Sarcopenia has an impact on recurrence-free survival, but does not appear to have a negative impact on surgical outcomes or overall survival among endometrial cancer patients who undergo preoperative CT scan.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Time to recurrence and death by Kaplan-Meier analysis between patients with sarcopenia versus no sarcopenia. Kaplan-Meier survival curves comparing endometrial cancer patients with sarcopenia versus no sarcopenia. (A) Time to recurrence, log rank p = 0.02; (B) Overall survival, log rank p = 0.25.

References

    1. Studley. Percentage of weight loss: a basic indicator of surgical risk in patients with chronic peptic ulcer. Journal of American Medical Association. 1936;106:458–460. - PubMed
    1. Raslan M, Gonzalez MC, Torrinhas RS, et al. Complementarity of Subjective Global Assessment (SGA) and Nutritional Risk Screening 2002 (NRS 2002) for predicting poor clinical outcomes in hospitalized patients. Clin Nutr. 30(1):49–53. - PubMed
    1. Awad S, Lobo DN. What’s new in perioperative nutritional support? Curr Opin Anaesthesiol. 24(3):339–348. - PubMed
    1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137(4):231–243. - PubMed
    1. Baumgartner RN, Wayne SJ, Waters DL, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12(12):1995–2004. - PubMed

Publication types

MeSH terms

LinkOut - more resources